North America Scar Treatment Market To Witness Rapid Growth With Janssen Biotech, Inc. Completing Acquisition Of Bermekimab, An Anti-IL-1alpha Monoclonal Antibody, From Xbiotech
A scar is an area of fibrous tissue that replaces normal skin after an injury. Some scars are barely visible, while others may cause pain, restrict movement or affect sleep. Whether scars result from trauma, surgery, acne, or any other causes, treatments are out there to diminish their impact. There are even different kinds of scars, which depend on the underlying cause and appearance of the scars, so proper treatment must be sought and considered.
Increasing incidents of burns and
acne cases are expected to drive the growth of the North America scar treatment market. According to the Centers for Disease Control Prevention (CDC), around
1.1 million burn injuries in the U.S. require medical attention, while 4,500 of
these people die each year. Furthermore, around 10,000 people in the U.S. die
every year of burn-related infections. According to the American Academy of
Dermatology Association (AADA), around 85% of people between ages 12 to 24
experience at least minor acne, affecting around 50 million U.S. citizens
annually. As a result of this, scar treatment procedures have witnessed a
significant surge over the years. Scar treatment can remove any scar developed
on the skin and restore the appearance with an even tone and smooth texture.
Hence, such factors are expected to drive growth of the North America scar
treatment market. Furthermore, increasing number of cosmetic surgeries is
expected to propel the North America scar treatment market growth in the near
future.
However, high cost associated with
laser treatment and side effects such as temporary burning discomfort,
crusting, infections, and edema is expected to restrain growth of the North
America scar treatment market. That being said, technological advancements in
laser surgeries and rising demand for silicone-based products can provide
significant business opportunities in the North America scar treatment market.
Besides, rising adoption of ablative laser resurfacing (ALR) can pose major
business opportunities for market players.
Key players involved in the North
America scar treatment market are Cynosure, Inc., Syneron Medical Ltd., Smith
& Nephew Inc., Luminus Inc., Merz Inc., NutraMarks, Inc., Enaltus LLC,
Janssen Biotech, Inc., Oculus Innovative Sciences, Inc., Lutronics, CCA
Industries, and Avita Medical.
For instance, in December 2019,
Janssen Biotech, Inc. acquired Investigational Bermekimab, an anti-IL-1alpha
monoclonal antibody (mAb) in Phase 2 development for the treatment of atopic
dermatitis and hidradenitis suppurativa, from XBiotech.
Comments
Post a Comment